FT : Germany agrees budget deal to plug €17bn hole after debt ruling

Germany agrees budget deal to plug €17bn hole after debt ruling
Olaf Scholz’s coalition seals 2024 spending plan after approving deep cuts to transport, industry and green projects

Germany’s government has clinched a last-minute budget deal, averting a financial shutdown in January and plugging a projected €17bn hole opened by a landmark court ruling. 

After weeks of tense negotiations, Olaf Scholz’s coalition agreed painful cuts to green energy and construction subsidies, transport spending and support measures for industry in order to comply with Berlin’s strict public finance rules.

Funding for Ukraine against Russia’s full-scale invasion and social security spending would be protected, the chancellor said. The government will also raise the carbon price more than planned next year.

Scholz acknowledged the tougher financial environment ahead for the EU’s largest economy, which is forecast to have only a small rebound in gross domestic product next year.

“The government is sticking to its goals. We are forging ahead with the climate-neutral transformation of our country,” Scholz said on Wednesday. “We are strengthening social cohesion and we are standing by Ukraine’s side in its defence against Russia . . . [but] it is clear that we must manage with significantly less money in order to achieve these goals.”

In a ruling last month, Germany’s top court declared that €60bn of funding allocated to its KTF special climate fund violated the country’s constitutionally enshrined debt brake, which tightly limits government borrowing, throwing financial planning for 2024 into disarray. 

Scholz said the government would not seek to repeal the debt brake next year, despite the long-term questions keeping it has raised in Germany. The brake prohibits Germany from running a fiscal deficit exceeding 0.35 per cent of GDP. It had been suspended for four years as a result of the coronavirus pandemic and the energy crisis fuelled by deep cuts in imports from Russia after its invasion of Ukraine last year.

The chancellor said that if the situation in Ukraine deteriorated, the government was prepared to seek emergency funding through a partial suspension of debt brake rules in the coming months.

Some painful cuts to environmental policies were necessary, said vice-chancellor Robert Habeck, of the Green party. “That’s the price we have to pay for retaining the central components . . . development of the hydrogen economy, decarbonisation of industry and citizens’ programmes.”

The KTF will have its spending plans cut by €12bn next year, the government said, while environmental subsidies for homeowners would also be scaled back.

Government funding for Germany’s railways will be reduced, though the shortfall will be plugged with a plan to sell off real estate around the rail network.

In a partial offset to curbs on green policies, €3bn of subsidies earmarked for polluting industries will also be cut.

Finance minister Christian Lindner, of the fiscally hawkish Free Democratic party, welcomed the agreement and said it showed Germany was committed to a “course of fiscal consolidation”.

A €15bn package of tax cuts for households would go ahead as planned, Lindner said, as well as a €3bn reduction in electricity taxes.

The budget deficit will shrink again next year, he said, to 1.5 per cent. It was 3.6 per cent in 2021.

“We have achieved a turnaround . . . the debt brake continues to be of great importance to us. I think this is a balanced, good package that will move our country forward.”

>>> US Research Calls

Research Calls I
  • Upgrades:
    • Ally Financial (ALLY) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $31
    • ArcelorMittal (MT) upgraded to Overweight from Neutral at JP Morgan (yesterday)
    • BASF AG (BASFY) upgraded to Buy from Sell at UBS
    • C4 Therapeutics (CCCC) upgraded to Buy from Hold at Stifel; tgt raised to $12
    • Capital One (COF) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $120
    • D.R. Horton (DHI) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $164
    • Gogoro (GGR) upgraded to Neutral from Underweight at JP Morgan
    • Health Catalyst (HCAT) upgraded to Overweight from Neutral at JP Morgan; tgt lowered to $11
    • Incyte (INCY) upgraded to Outperform from Market Perform at Leerink Partners; tgt $78
    • MFA Financial (MFA) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $12
    • Mohawk (MHK) upgraded to Equal Weight from Underweight at Barclays; tgt raised to $100
    • MSCI (MSCI) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $600
    • Opendoor Technologies (OPEN) upgraded to Mkt Perform from Underperform at Keefe Bruyette; tgt $3.50
    • Pentair (PNR) upgraded to Overweight from Sector Weight at KeyBanc Capital Markets; tgt $82
    • Q2 Holdings (QTWO) upgraded to Neutral from Underweight at Piper Sandler; tgt raised to $41
    • Radian Group (RDN) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt $29
    • Realty Income (O) upgraded to Outperform from Neutral at Exane BNP Paribas; tgt $63
    • RxSight (RXST) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $42
    • Volkswagen AG (VWAGY) upgraded to Neutral from Underperform at Exane BNP Paribas
    • Xponential Fitness (XPOF) upgraded to Buy from Hold at Stifel; tgt $18
  • Downgrades:
    • Agree Realty (ADC) downgraded to Neutral from Outperform at Exane BNP Paribas; tgt $64
    • Aveanna (AVAH) downgraded to Underweight from Neutral at JP Morgan
    • Bread Financial (BFH) downgraded to Underweight from Equal-Weight at Morgan Stanley; tgt lowered to $25
    • Church & Dwight (CHD) downgraded to Sell from Neutral at Citigroup; tgt $90
    • Coherent (COHR) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt raised to $45
    • Ferrari (RACE) downgraded to Neutral from Outperform at Exane BNP Paribas
    • Ferrari (RACE) downgraded to Hold from Buy at HSBC Securities
    • Ford Motor (F) downgraded to Neutral from Outperform at Exane BNP Paribas; tgt $12
    • Hertz Global (HTZ) downgraded to Perform from Outperform at Oppenheimer
    • Hillman Solutions Corp. (HLMN) downgraded to Equal Weight from Overweight at Barclays; tgt $9
    • Inspire Medical Systems (INSP) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $187
    • Johnson Controls (JCI) downgraded to Hold from Buy at Vertical Research; tgt $55
    • Johnson & Johnson (JNJ) downgraded to Equal Weight from Overweight at Wells Fargo; tgt lowered to $163
    • LyondellBasell (LYB) downgraded to Neutral from Buy at Citigroup; tgt lowered to $98
    • Model N (MODN) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $25
    • NETSTREIT (NTST) downgraded to Neutral from Outperform at Exane BNP Paribas; tgt $17
    • NexPoint Real Estate Finance (NREF) downgraded to Mkt Perform from Outperform at Keefe Bruyette
    • R1 RCM (RCM) downgraded to Neutral from Overweight at JP Morgan; tgt lowered to $11
    • Shell plc (SHEL) downgraded to Neutral from Outperform at Exane BNP Paribas
    • Trex (TREX) downgraded to Underweight from Equal Weight at Barclays; tgt raised to $74
    • Visteon (VC) downgraded to Neutral from Outperform at Exane BNP Paribas; tgt $130
    • Walker & Dunlop (WD) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt raised to $105
    • Western Midstream (WES) downgraded to Underperform from Buy at BofA Securities; tgt lowered to $27
    • WPP plc (WPP) downgraded to Neutral from Overweight at JP Morgan
    • Zurn Elkay Water Solutions (ZWS) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets
  • Others:
    • 10x Genomics (TXG) initiated with an Outperform at Wolfe Research; tgt $55
    • ACADIA Pharmaceuticals (ACAD) initiated with a Buy at Citigroup; tgt $38
    • ACELYRIN (SLRN) initiated with an Equal Weight at Wells Fargo; tgt $11
    • Advance Auto (AAP) resumed with a Mkt Perform at William Blair
    • Agilent (A) initiated with an Outperform at Wolfe Research; tgt $140
    • Aris Water Solutions (ARIS) initiated with a Buy at Seaport Research Partners; tgt $15
    • Alphabet (GOOG/L) named new Top Pick at JP Morgan
    • Arcturus Therapeutics (ARCT) initiated with a Buy at Canaccord Genuity; tgt $90
    • AutoZone (AZO) resumed with an Outperform at William Blair
    • Axsome Therapeutics (AXSM) initiated with a Buy at Citigroup; tgt $125
    • Bruker (BRKR) initiated with an Outperform at Wolfe Research; tgt $80
    • Camping World (CWH) initiated with a Buy at ROTH MKM; tgt $30
    • CAVA Group (CAVA) initiated with an Outperform at TD Cowen; tgt $46
    • CCC Intelligent Solutions (CCCS) resumed with a Neutral at Citigroup; tgt $13
    • Cricut (CRCT) initiated with a Neutral at Goldman; tgt $7
    • Danaher (DHR) resumed with a Peer Perform at Wolfe Research
    • Denali Therapeutics (DNLI) initiated with a Buy at Citigroup; tgt $32
    • DoubleVerify (DV) initiated with an Overweight at Morgan Stanley; tgt $40
    • Exact Sciences (EXAS) initiated with an Outperform at Wolfe Research; tgt $95
    • Guardant Health (GH) initiated with a Peer Perform at Wolfe Research
    • HilleVax (HLVX) initiated with a Buy at H.C. Wainwright; tgt $28
    • Impinj (PI) initiated with a Positive at Susquehanna; tgt $100
    • Illumina (ILMN) initiated with an Outperform at Wolfe Research; tgt $175
    • Kanzhun Limited (BZ) initiated with an Overweight at JP Morgan; tgt $20
    • Microsoft (MSFT) initiated with a Buy at Truist
    • Myriad Genetics (MYGN) initiated with an Outperform at Wolfe Research; tgt $28
    • Natera (NTRA) initiated with an Outperform at Wolfe Research; tgt $70
    • Neurocrine Biosciences (NBIX) resumed with a Buy at William O'Neil
    • Neurocrine Biosciences (NBIX) resumed with a Neutral at Citigroup; tgt $127
    • Opera (OPRA) initiated with a Buy at Goldman; tgt $16.50
    • Pacific Biosciences (PACB) initiated with a Peer Perform at Wolfe Research
    • Qiagen (QGEN) initiated with a Peer Perform at Wolfe Research
    • Revvity (RVTY) initiated with a Peer Perform at Wolfe Research
    • Roblox (RBLX) initiated with an Overweight at Wells Fargo; tgt $49
    • Sarepta Therapeutics (SRPT) resumed with a Buy at Citigroup; tgt $113
    • Standex International (SXI) initiated with a Buy at DA Davidson; tgt $165
    • Thermo Fisher (TMO) initiated with an Outperform at Wolfe Research; tgt $575
    • Veralto (VLTO) initiated with a Peer Perform at Wolfe Research
    • VIZIO (VZIO) initiated with a Buy at B. Riley Securities; tgt $11
    • Xylem (XYL) initiated with an Outperform at Wolfe Research; tgt $127

FT : 6G: network operators want profitable returns on 5G first

6G: network operators want profitable returns on 5G first
Before the next generation of wireless communications is rolled out, better take-up of this one is needed

This month, a consortium of global telecoms standards organisations declared plans to work on a sixth generation of superfast wireless cellular communications specifications. But consumer take-up of 5G has been lacklustre. One wonders whether 6G, due out next decade, will attract much attention.

Mobile carriers such as Verizon, AT&T and T-Mobile promised that 5G networks would transform our lives. Auctions for bandwidth hit a record in 2021 when Verizon bid more than $45bn. Yet many smartphone customers struggle to notice any difference.

About two-thirds of US mobile phone customers have tried 5G networks, according to a survey by Global Wireless Solutions. Still, ABI Research expects more subscribers to use 4G by the end of 2023.

Blame the way in which 5G was rolled out. Upgrades were piecemeal and offered little improvement. Extra speed, capacity and connectivity available on standalone networks have yet to be used fully.

The 4G networks released in the early 2010s enabled mobile phone users to stream videos, play games and make conference calls. 5G can be used for high-quality virtual and augmented reality and allow instant communication between devices such as autonomous vehicles. But these latest functions have yet to gain mass appeal.

New 6G could enable data speeds up to 50 or 100 times faster than 5G. Companies such as Huawei and Nokia say it should be ready to roll out in the early 2030s. Both the US and China are determined not to let the other gain an advantage.

However, data from CB Insights shows that mentions of 5G during earnings calls peaked in 2021 and have since fallen. Network operator capital spending growth is expected to dip next year. Operators want to see better returns on their investment in 5G before they contemplate further network upgrades.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • PFE -6.8% (guidance; also announces changes to its commercial ops following SGEN acquisition), LUV -2.6% (guidance)
Other news:
  • SOS -3.3% (ADS offering)
  • BDTX -2.8% (announces topline results from phase 1 dose escalation trial of BDTX-1535)
  • TH -2.5% (announces details of $3.3 billion contract award for Pecos humanitarian community; updates 2023 guidance introduces 2024 guidance)
  • XPEV -2.3% (BABA discloses a 12.5% passive stake)
Analyst comments:
  • AVAH -4.7% (downgraded to Underweight from Neutral at JP Morgan)
  • BFH -2.7% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
  • CHD -1.3% (downgraded to Sell from Neutral at Citigroup)
  • RACE -1.3% (downgraded to Neutral from Outperform at Exane BNP Paribas; downgraded to Hold from Buy at HSBC Securities)
  • COHR -1.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • ABM +7.1%, PLAB +5%, CGNT +4.3%, REVG +3.9%
Other news:
  • CCCC +15% (announces CFT7455 Phase 1 trial data)
  • LFMD +12.5% (LifeMD and Medifast (MED) partner to offer transformative weight management solution)
  • VSTM +10.4% (initiation of a confirmatory phase 3 trial of avutometinib and defactinib in recurrent low-grade serous ovarian cancer)
  • VRTX +7.2% (Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy)
  • CRBU +5.8% (provides regulatory update on CB-010 with Phase 3 trial initiation expected by YE24)
  • TTWO +3.4% (Take-Two Interactive Software (TTWO) will be added to the Nasdaq-100 Index)
  • BBAI +3% (awarded $17.9 mln extension on Phase 2 of U.S. Army GFIM OTA)
  • WSR +2.7% (Board of Trustees responds to proposal from Bruce Schanzer / Erez Asset Management)
  • COMP +2.6% (COO to depart; COO role to be eliminated)
  • HCM +2.6% (completed enrollment of a Phase II/III Trial of Fruquintinib in combination with Sintilimab for advanced renal cell carcinoma in China; announces continued inclusion of ELUNATE and SULANDA in the National Reimbursement Drug List in China at current terms)
  • TTC +2.4% (increases dividend)
  • VERX +2.3% (Offers to acquire Pagero)
  • MED +2.1% (initiates business transformation by entering the medically supported weight loss market through collaboration with LifeMD (LFMD); MED to discontinue the company's quarterly cash dividend effective immediately)
  • RPT +1.9% (RPT shareholders approve previously announced merger with KIM)
  • ZLAB +1.7% (First Listing of VYVGART (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List)
  • VET +1.6% (announces 2024 budget and updated return of capital framework; increases dividend)
  • ATS +1.5% (announces normal course issuer bid)
  • HBNC +1.3% (executes a balance sheet repositioning)
  • ABNB +1.2% (provided an update on the Italian tax authorities' tax assessment of 779 million euros on Airbnb's Irish subsidiary)
Analyst comments:
  • ALLY +1.3% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
  • QTWO +1.2% (upgraded to Neutral from Underweight at Piper Sandler)
  • OPEN +0.6% (upgraded to Mkt Perform from Underperform at Keefe Bruyette)

WSJ : Oaktree Raises About $3 Billion for Latest Special-Situations Fund

Oaktree Raises About $3 Billion for Latest Special-Situations Fund
The distressed-investing giant’s new fund makes private-equity and debt investments in midmarket businesses

Oaktree Capital Management has closed its third special-situations fund to invest in midmarket companies struggling with high debt or other financial challenges.

Oaktree wrapped up fundraising for its Special Situations Fund III with about $3 billion, including commitments to related vehicles, people familiar with the matter said. The sum exceeds the Los Angeles firm’s initial target of $2.5 billion and the $2.3 billion raised by a 2018-vintage predecessor fund, the people said.

Investors that committed to the new pool as limited partners include the Minnesota State Board of Investments and the Teachers’ Retirement System of Louisiana, according to public pension-fund documents.

Oaktree amassed the sum during a difficult time for raising capital for private-equity and private-debt vehicles aimed at backing companies under financial stress. Such funds surged in popularity in 2020 and early 2021, as the Covid pandemic spurred high rates of corporate defaults and created an abundance of investment opportunities, but they have since struggled to gain traction among investors.

Funds that invest in distressed debt raised just under $10 billion globally from the start of the year through Oct. 27, down from about $32 billion in 2022 and $37 billion in 2021, according to PitchBook Data, which collects information about private markets.

Oaktree’s fundraising effort may have been boosted by a strong performance so far by the credit specialist’s previous special-situations fund. It posted an internal rate of return of about 45% through June, according to data from the School Employees Retirement System of Ohio, which backed the vehicle.

Oaktree manages about $183 billion across debt, private equity, real assets and other strategies. Founded in 1995, Oaktree went public in 2012, and was taken private again in 2019 by Canadian asset-management firm Brookfield.

Oaktree’s special-situations funds are more like private-equity funds than distressed-debt vehicles, though they invest in both debt and equity. The funds are intended to thrive in good and bad financial conditions, targeting private equity-like returns by backing companies contending with temporary financial issues.

Oaktree’s special-situations funds typically invest around $125 million to $150 million per deal in North American midmarket companies broadly across industries and sectors. The funds aim for control or significant influence over the businesses they back. So far, the firm has invested about $1 billion from its new vehicle.

Companies backed by Oaktree’s special-situations strategy include MBS Group, which provides services to film and television studios, and barbecue grill maker Blackstone Products.

>>> Pfizer reaffirms FY23 guidance, sees FY24 EPS and revenue below consensus in

Pfizer reaffirms FY23 guidance, sees FY24 EPS and revenue below consensus including expected contribution from Seagen acquisition (28.58)
  • Co reaffirms guidance for FY23 (Dec), sees EPS of $1.45-1.65 vs. $1.73 FactSet Consensus; sees FY23 (Dec) revs of $58-61 bln vs. $59.65 bln FactSet Consensus.
  • Co issues downside guidance for FY24 (Dec), sees EPS of $2.05-2.25 vs. $3.17 FactSet Consensus; sees FY24 (Dec) revs of $58.5-61.5 bln vs. $62.66 bln FactSet Consensus.
  • Pfizer expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty and Paxlovid, approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer's royalty income from Other (Income)/Deductions into the Revenue line. Including the contribution from Seagen and excluding revenues from Comirnaty(2) and Paxlovid, Pfizer expects to achieve full-year 2024 operational(3) revenue growth of 8% to 10%. Excluding revenues from Comirnaty(2) and Paxlovid and the expected contribution from Seagen, Pfizer expects to achieve full-year 2024 operational(3) revenue growth of 3% to 5%. Both expected operational(3) growth rate ranges are compared with the mid-point of Pfizer's full-year 2023 revenue guidance range provided on October 31, 2023, and account for the reclassification of royalty income. While the company will begin reporting royalty income in the revenue line in 2024, for growth rate purposes, the company has included royalty income in both 2023 and 2024. Consequently, there is no operational revenue growth attributable to the reclassification of royalty income.
  • Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated: "Pfizer's product portfolio remains strong. In 2024, Comirnaty and Paxlovid are expected to deliver combined revenues of approximately $8 billion and our remaining portfolio of combined Pfizer and Seagen products is expected to achieve year-over-year operational revenue growth in the range of 8% to 10%. "In addition, we expect our cost realignment program to deliver savings of at least $4.0 billion by the end of 2024, which puts us on a path to potentially regain our pre-pandemic operating margins."

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • CCCC +7.5%, BBAI +6.6%, LFMD +6.4%, SLM +3.8%, TTWO +3.4%, CRBU +2.8%, COMP +2.6%, HCM +2.6%, TTC +2.4%, VERX +2.3%, VET +1.4%, HBNC +1.3%, PLAB +1.3%, ABNB +1.1%, VRTX +1.1%, CVLY +0.8%, UGI +0.7%
  • Gapping down:
    • SOS -3.3%, XPEV -2.8%, SHEL -0.6%, WBD -0.5%